Biodexa Pharmaceuticals (BDRX) Competitors $1.30 -0.02 (-1.52%) Closing price 03:59 PM EasternExtended Trading$1.30 0.00 (0.00%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. ADCT, SCPH, NBTX, DMAC, INBX, PRQR, INMB, PBYI, OGI, and PRMEShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include ADC Therapeutics (ADCT), scPharmaceuticals (SCPH), Nanobiotix (NBTX), DiaMedica Therapeutics (DMAC), Inhibrx (INBX), ProQR Therapeutics (PRQR), INmune Bio (INMB), Puma Biotechnology (PBYI), Organigram (OGI), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. ADC Therapeutics scPharmaceuticals Nanobiotix DiaMedica Therapeutics Inhibrx ProQR Therapeutics INmune Bio Puma Biotechnology Organigram Prime Medicine ADC Therapeutics (NYSE:ADCT) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Is ADCT or BDRX more profitable? Biodexa Pharmaceuticals has a net margin of 0.00% compared to ADC Therapeutics' net margin of -300.00%. Company Net Margins Return on Equity Return on Assets ADC Therapeutics-300.00% N/A -61.33% Biodexa Pharmaceuticals N/A N/A N/A Which has more risk & volatility, ADCT or BDRX? ADC Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Do institutionals & insiders have more ownership in ADCT or BDRX? 41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor ADCT or BDRX? ADC Therapeutics received 62 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 69.23% of users gave ADC Therapeutics an outperform vote. CompanyUnderperformOutperformADC TherapeuticsOutperform Votes6369.23% Underperform Votes2830.77% Biodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo Votes Which has better earnings and valuation, ADCT or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADC Therapeutics$70.84M2.74-$240.05M-$1.45-1.35Biodexa Pharmaceuticals$83K572.38-$7.66MN/AN/A Does the media prefer ADCT or BDRX? In the previous week, ADC Therapeutics had 13 more articles in the media than Biodexa Pharmaceuticals. MarketBeat recorded 14 mentions for ADC Therapeutics and 1 mentions for Biodexa Pharmaceuticals. Biodexa Pharmaceuticals' average media sentiment score of 0.80 beat ADC Therapeutics' score of 0.48 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodexa Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ADCT or BDRX? ADC Therapeutics presently has a consensus price target of $7.75, indicating a potential upside of 296.42%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ADC Therapeutics is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryADC Therapeutics beats Biodexa Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.51M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E RatioN/A8.9226.8419.71Price / Sales572.38253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.036.466.794.50Net Income-$7.66M$143.98M$3.23B$248.18M7 Day Performance-0.76%3.04%4.07%1.14%1 Month Performance-5.80%7.44%12.52%15.20%1 Year PerformanceN/A-2.46%16.83%6.56% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.8807 of 5 stars$1.30-1.5%N/AN/A$47.51M$83,000.000.0020News CoverageADCTADC Therapeutics2.6699 of 5 stars$2.34+23.8%$7.75+231.2%-47.8%$187.45M$70.84M-0.98310News CoverageEarnings ReportAnalyst RevisionHigh Trading VolumeSCPHscPharmaceuticals4.1032 of 5 stars$3.52+9.3%$14.00+297.7%-18.6%$185.83M$41.98M-1.8530Earnings ReportAnalyst RevisionHigh Trading VolumeNBTXNanobiotix1.6897 of 5 stars$3.94+2.1%$8.00+103.0%-46.1%$185.70M$-11,609,000.000.00100News CoverageDMACDiaMedica Therapeutics1.4905 of 5 stars$4.27+1.7%$8.00+87.4%+35.3%$183.11MN/A-7.6220News CoverageAnalyst RevisionGap UpHigh Trading VolumeINBXInhibrx1.8879 of 5 stars$12.47+1.1%N/A-62.1%$180.52M$200,000.000.11166Earnings ReportPRQRProQR Therapeutics3.1895 of 5 stars$1.71+5.6%$8.00+367.8%-8.3%$179.91M$18.97M-5.34180INMBINmune Bio1.9353 of 5 stars$7.77-1.1%$22.80+193.4%-31.6%$178.59M$50,000.00-3.5610Positive NewsGap DownPBYIPuma Biotechnology3.5529 of 5 stars$3.58+5.6%$7.00+95.5%-16.9%$177.68M$232.71M7.46200OGIOrganigram0.2552 of 5 stars$1.31-3.7%N/A-32.2%$175.33M$194.09M-3.45860Gap DownPRMEPrime Medicine3.7023 of 5 stars$1.34-16.0%$12.60+843.8%-84.4%$175.28M$3.85M-0.65234Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading Volume Related Companies and Tools Related Companies ADC Therapeutics Competitors scPharmaceuticals Competitors Nanobiotix Competitors DiaMedica Therapeutics Competitors Inhibrx Competitors ProQR Therapeutics Competitors INmune Bio Competitors Puma Biotechnology Competitors Organigram Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
